Gonadorelin

What Gonadorelin Does

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH) — the master regulator of the reproductive endocrine system. The hypothalamus naturally releases GnRH in pulsatile bursts approximately every 60-90 minutes, and each pulse triggers the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH drives testosterone production in testicular Leydig cells; FSH drives spermatogenesis in Sertoli cells. This hypothalamic-pituitary-gonadal (HPG) axis is the fundamental control loop for male reproductive function.

Gonadorelin’s clinical relevance surged after 2020 when HCG compounding restrictions forced TRT clinics to find alternatives for maintaining fertility and testicular function in men on testosterone therapy. It is also used in post-cycle therapy (PCT) after anabolic steroid or SARM cycles.

The mechanisms that matter:

• Pulsatile GnRH receptor stimulation — when administered intermittently (2-3x per week), Gonadorelin mimics the natural pulsatile release pattern from the hypothalamus. Each pulse stimulates GnRH receptors on pituitary gonadotroph cells, triggering LH and FSH secretion. This is the physiological signal that maintains the entire reproductive cascade
• LH stimulation for testosterone — the LH released by pituitary stimulation acts on Leydig cells in the testes to produce testosterone. Unlike exogenous testosterone (TRT) or HCG (which mimics LH directly), Gonadorelin works through the natural pathway — hypothalamus to pituitary to testes
• FSH stimulation for spermatogenesis — FSH acts on Sertoli cells to support sperm production. This is Gonadorelin’s key advantage over HCG, which primarily stimulates LH-like activity and has limited FSH effects. For men concerned about fertility during TRT, FSH maintenance is critical
• HPG axis preservation — by keeping the pituitary engaged and responsive to GnRH, Gonadorelin prevents the pituitary atrophy/desensitization that occurs during prolonged HPG suppression from TRT or AAS use

The Critical Concept: Pulsatile vs Continuous

This is not a detail — it is the entire pharmacology:

Dosing Pattern	Pituitary Response	Clinical Effect
Pulsatile (2-3x per week)	GnRH receptors upregulate; LH/FSH release	Stimulation — testosterone and sperm production increase
Continuous (daily or constant infusion)	GnRH receptors downregulate; LH/FSH suppression	Suppression — testosterone and sperm production decrease

This paradox is the basis of GnRH agonist drugs used in prostate cancer treatment (leuprolide/Lupron, goserelin/Zoladex). These drugs provide continuous GnRH stimulation, which initially causes a testosterone “flare” but within 2-3 weeks produces profound chemical castration through receptor downregulation.

Do not use Gonadorelin daily. Daily or more frequent dosing risks continuous exposure, which will suppress — not stimulate — LH and FSH. The 2-3x per week protocol is specifically designed to provide pulsatile stimulation with adequate recovery periods between doses.

Gonadorelin vs HCG Comparison

Feature	Gonadorelin	HCG
Mechanism	Stimulates pituitary to release LH + FSH	Mimics LH directly at testes
Site of action	Upstream (pituitary)	Downstream (testes)
LH stimulation	Indirect (via pituitary)	Direct (LH-mimetic)
FSH effect	Yes — stimulates both LH and FSH	Minimal — primarily LH-like
Pituitary preservation	Yes — keeps pituitary active	No — pituitary remains suppressed
Testicular response	Requires functional pituitary	Works regardless of pituitary status
Reliability	Variable (pituitary may be desensitized)	Highly reliable
Half-life	~10-40 minutes	~24-36 hours
FDA status	Approved (Factrel, diagnostic)	Approved (multiple brands, fertility)
Compounding	Available	Restricted since 2020 (biologic reclassification)
Fertility support	Good (LH + FSH)	Moderate (primarily LH)
Cost	Lower	Higher (brand-name); variable (compounded)

When Gonadorelin is the better choice: Fertility preservation (FSH effect), pituitary function maintenance, patients who want the most physiological approach, situations where HCG is unavailable or cost-prohibitive.

When HCG is the better choice: Proven HPG suppression where pituitary may not respond, primary goal is testicular atrophy prevention, need for reliable testosterone stimulation regardless of pituitary status.

The 2020 HCG Crisis and Its Aftermath

In March 2020, the FDA’s reclassification of HCG as a biologic under the Biologics Price Competition and Innovation Act (BPCIA) sent shockwaves through the TRT community. Compounding pharmacies — which had been the primary affordable source of HCG for thousands of TRT patients — could no longer produce it under standard compounding exemptions. Brand-name HCG (Pregnyl, Novarel) costs $200-400+ per month compared to $30-60 for compounded.

The result was a rapid, large-scale pivot to Gonadorelin. TRT clinics including Defy Medical, Viking Alternative Medicine, and dozens of others switched their patients from HCG 500-1,000 IU 2-3x/week to Gonadorelin 100-200 mcg 2-3x/week. Clinical outcomes have been mixed — some patients maintain adequate LH/FSH and testicular function on Gonadorelin, while others experience insufficient stimulation and require brand-name HCG or alternative approaches (enclomiphene, kisspeptin).

Some 503B outsourcing facilities were later able to continue producing HCG, partially restoring availability. But the episode established Gonadorelin as a legitimate, if imperfect, alternative in the TRT fertility maintenance toolkit.

Monitoring Your Response

Blood work is essential — Gonadorelin’s effects must be verified biochemically, not assumed:

• LH and FSH — should rise into the normal range (LH 1.8-8.6 mIU/mL, FSH 1.5-12.4 mIU/mL) within 4-6 weeks of starting
• Total and free testosterone — if using for PCT, should recover to >300 ng/dL minimum (ideally >500 ng/dL)
• Estradiol — monitor for appropriate levels; rising testosterone increases aromatization
• Semen analysis — if fertility is the goal, check after 3-6 months (full spermatogenesis cycle is ~74 days)
• Testicular ultrasound — if atrophy prevention is a concern, periodic imaging can objectively assess testicular volume

Dosing Protocol

Standard Protocol

Parameter	Detail
Dose	100–200 mcg per injection
Frequency	2–3 times per week (pulsatile — never daily)
Route	Subcutaneous injection
Duration	4–12 weeks (PCT) or ongoing (fertility maintenance during TRT)
Best timing	Morning (aligns with natural LH pulsatility)

Dose Tiers

Use Case	Dose	Frequency	Duration
Fertility maintenance during TRT	100 mcg	2x per week	Ongoing (concurrent with TRT)
Standard fertility support	200 mcg	2x per week	Ongoing or until conception
PCT after mild suppression (SARMs)	100 mcg	3x per week	4–6 weeks
PCT after moderate suppression (AAS cycle)	200 mcg	3x per week	8–12 weeks
Diagnostic (Factrel protocol)	100 mcg	Single dose (IV or SubQ)	One-time

Timing Guidance

• Morning dosing preferred — LH has a natural pulsatile pattern with higher amplitude pulses in the early morning. Dosing in the morning aligns with this physiology
• Even spacing — if dosing 3x per week, space doses evenly (e.g., Monday/Wednesday/Friday). If 2x per week, space by 3-4 days (e.g., Monday/Thursday)
• Consistency — dose at the same time on injection days
• With TRT: Inject Gonadorelin on different days than testosterone injections if possible, to avoid confounding the hormonal signal

Reconstitution

For a 2 mg vial — add 2 mL bacteriostatic water:

Dose	Volume to Draw
100 mcg	10 units on insulin syringe
150 mcg	15 units
200 mcg	20 units

Concentration: 1,000 mcg/mL (1 mg/mL). A 2 mg vial provides 10-20 doses depending on dose used.

Storage: Refrigerate at 2-8°C after reconstitution. Use within 28 days. Gonadorelin is a relatively stable decapeptide in solution. Unreconstituted powder can be stored at room temperature for months or frozen for longer-term storage.

Cycling

Cycling depends on the use case:

During TRT (fertility maintenance): No cycling — use continuously as long as TRT continues. The goal is to maintain pituitary LH/FSH output and testicular function for the entire duration of testosterone therapy. Discontinue Gonadorelin when TRT is discontinued (as the HPG axis will naturally resume without exogenous testosterone suppressing it).

Post-cycle therapy (PCT): Run for 4-12 weeks depending on the degree of HPG suppression:

• After SARMs (mild suppression): 4-6 weeks
• After a standard AAS cycle (moderate suppression): 8-12 weeks
• After prolonged AAS use (severe suppression): 8-12 weeks of Gonadorelin + SERM combination

PCT combination protocol (common):

• Weeks 1-8: Gonadorelin 200 mcg 3x/week + Enclomiphene 25 mg/day (or Clomiphene 25-50 mg/day)
• Weeks 9-12: Gonadorelin 100 mcg 2x/week + Enclomiphene 12.5 mg/day (taper)

The SERM blocks estrogen’s negative feedback on the hypothalamus, increasing GnRH release. Gonadorelin directly stimulates the pituitary. The combination attacks HPG recovery from two angles.

What to Expect

Week 1

• No noticeable hormonal changes — the HPG axis responds slowly to stimulation
• If transitioning from HCG to Gonadorelin during TRT, there may be a brief dip in intratesticular testosterone as the body adjusts from direct LH mimicry to pituitary-mediated LH release
• Injection is straightforward — small volume, subcutaneous

Weeks 2-4

• LH and FSH levels begin to rise — measurable on blood work by week 2-3
• If using for PCT: testosterone levels start climbing as Leydig cells respond to increasing LH
• Testicular volume may increase slightly if prior suppression had caused atrophy
• Energy and mood may begin to improve as testosterone normalizes (in PCT scenarios)

Weeks 4-8

• Hormonal stabilization — LH, FSH, and testosterone approach baseline or target levels
• If using during TRT for fertility: sperm parameters (count, motility) may begin improving. Full spermatogenesis takes 72-90 days, so complete recovery requires longer treatment
• If using for PCT: most of the hormonal recovery should be evident by week 6-8. Blood work at this point determines whether to continue or taper

Weeks 8-12+

• Fertility parameters maturing — spermatogenesis requires approximately 74 days for a full cycle of sperm production. Meaningful improvements in sperm count typically require 3-6 months of treatment
• PCT: if recovery is adequate (testosterone >300 ng/dL, LH in normal range), Gonadorelin can be tapered and discontinued
• Long-term fertility maintenance: continue indefinitely during TRT

What the Research Says

Gonadorelin’s pharmacology is extremely well-understood — GnRH biology is one of the most thoroughly studied areas in reproductive endocrinology.

GnRH pulsatility (Knobil, 1980, Science): Ernst Knobil’s landmark work in rhesus monkeys demonstrated that pulsatile GnRH administration (one pulse per hour) restored normal LH/FSH secretion and reproductive function, while continuous GnRH infusion produced paradoxical suppression. This fundamental discovery established the pulsatile dosing principle that governs all GnRH therapeutic applications. Published in Science and awarded the Lasker Prize.

Factrel diagnostic studies: The FDA approval of Gonadorelin (Factrel) was based on diagnostic studies showing that a single 100 mcg IV or SubQ injection reliably stimulates LH release in healthy subjects. The LH response (measured at 15-45 minutes post-injection) distinguishes pituitary dysfunction from hypothalamic dysfunction — if the pituitary responds to exogenous GnRH but LH is otherwise low, the problem is hypothalamic; if the pituitary does not respond, the problem is pituitary.

Pulsatile GnRH for hypogonadotropic hypogonadism (Crowley et al., New England Journal of Medicine): Pulsatile GnRH therapy administered via subcutaneous pump (every 90-120 minutes) successfully restored testosterone levels and spermatogenesis in men with hypothalamic hypogonadism. This is the gold standard for demonstrating that pulsatile GnRH restores full HPG function. Published in NEJM.

Gonadorelin vs HCG for TRT fertility maintenance (clinical practice data): Since the 2020 HCG compounding restrictions, multiple TRT clinics have published outcomes comparing Gonadorelin to HCG for maintaining testicular function during testosterone therapy. Results are mixed — Gonadorelin maintains LH/FSH levels in most patients but appears less reliable than HCG for preventing testicular atrophy, likely because pituitary GnRH sensitivity is partially reduced during TRT. Some patients require higher doses (200 mcg) or more frequent dosing (3x/week) to achieve effects comparable to HCG.

GnRH agonists for prostate cancer (Lupron, Zoladex): These drugs use continuous GnRH exposure to suppress testosterone to castrate levels. While they are different drugs than Gonadorelin (they use long-acting analogs), their mechanism confirms the critical principle: continuous GnRH = suppression. This is why Gonadorelin must never be dosed daily.

Key practitioner context:

• Many TRT clinics (Defy Medical, Marek Health, PeterMD) adopted Gonadorelin after the HCG restrictions, with protocols typically at 100-200 mcg 2-3x per week
• Derek (More Plates More Dates) has covered the HCG-to-Gonadorelin transition, noting that clinical responses are more variable with Gonadorelin and some patients require HCG for adequate testicular maintenance

Safety

Side Effects

Side Effect	Frequency	Notes
Injection-site reaction	~5-10%	Mild redness, transient
Headache	~5%	Usually mild and self-limiting
Flushing	~3-5%	Brief warmth sensation, resolves in minutes
Nausea	~3%	Mild, uncommon
Abdominal discomfort	~2%	Mild, transient
Lightheadedness	~2%	Rare, brief

Gonadorelin has an excellent safety profile. As a synthetic version of a naturally occurring hormone given at physiological doses, serious adverse events are extremely rare.

Critical Warnings

Never dose daily. This bears repeating because the consequences are the opposite of the intended effect. Daily Gonadorelin can cause GnRH receptor downregulation, leading to LH/FSH suppression and reduced testosterone — exactly what you are trying to prevent. Stick to 2-3 doses per week with at least 48 hours between doses.

It is not a guaranteed HCG replacement. Gonadorelin requires a functional, responsive pituitary. In men who have been on TRT for extended periods, pituitary GnRH sensitivity may be reduced. If LH/FSH remain suppressed despite 4-6 weeks of Gonadorelin therapy, the pituitary may need more time to recover sensitivity, or HCG may be necessary.

Blood work is essential. Monitor LH, FSH, total testosterone, free testosterone, and (if fertility is the goal) semen analysis. Gonadorelin’s effects should be verified biochemically — subjective assessment alone is insufficient.

Not appropriate for primary hypogonadism. If the testes themselves are the problem (primary testicular failure), Gonadorelin will stimulate LH/FSH release from the pituitary but the testes will not respond. Gonadorelin only works when the testes are functional but understimulated.

Combination with SERMs in PCT. When combining Gonadorelin with clomiphene or enclomiphene for PCT, monitor estradiol. Clomiphene’s anti-estrogenic effects can cause mood disturbances, visual symptoms, and estradiol dysregulation. Enclomiphene (the trans-isomer) is generally better tolerated.

Do Not Use If

• Women who are pregnant or may become pregnant (GnRH stimulation affects reproductive hormones unpredictably during pregnancy)
• Primary testicular failure (testes are non-functional — LH stimulation will not produce testosterone)
• GnRH-dependent tumors (pituitary adenomas, some prostate cancers)
• Known hypersensitivity to GnRH or GnRH analogs
• Under 18 (disruption of pubertal HPG axis development)

What Comes Next

• Address libido directly — PT-141 Protocol targets sexual desire through a complementary melanocortin pathway
• Comprehensive recovery — BPC-157 Protocol and TB-500 Protocol for tissue recovery during PCT
• Explore other protocols matched to your goals in the Directory
• Use the Reconstitution Calculator for precise dosing math